4,6-Dichloro-2-Methylpyrimidine CAS 1780-26-3 Purity ≥99.5% (GC) Hot Sale

Short Description:

Chemical Name: 4,6-Dichloro-2-Methylpyrimidine

CAS: 1780-26-3

Purity: ≥99.5% (GC)

Appearance: White or Off-White Crystalline Powder

Intermediate of Dasatinib / Moxonidine

Contact: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

1780-26-3 - Description:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 4,6-Dichloro-2-Methylpyrimidine (CAS: 1780-26-3) with high quality, commercial production. Intermediate of Dasatinib / Moxonidine. We can provide COA, worldwide delivery, small and bulk quantities available. Please contact: alvin@ruifuchem.com

1780-26-3 - Chemical Properties:

Chemical Name	4,6-Dichloro-2-Methylpyrimidine
Synonyms	2-Methyl-4,6-Dichloropyrimidine; 2,4-Dichloro-6-Methylpyrimidine; 2-MDCP
CAS Number	1780-26-3
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C5H4Cl2N2
Molecular Weight	163.00
Melting Point	41.5~45.5℃ (lit.)
Flash Point	208°F
Density	1.404±0.06 g/cm3
Solubility (Soluble in)	Methanol
COA & MSDS	Available
Place of Origin	Shanghai, China
Brand	Ruifu Chemical

1780-26-3 - Specifications:

Item	Specifications	Results
Appearance	White or Off-White Crystalline Powder	White Crystalline Powder
Purity / Analysis Method	≥99.5% (GC)	99.92%
Loss on Drying	≤0.50%	0.18%
Residue on Ignition	≤0.20%	0.05%
Single Impurity	≤0.50%	Conforms
Total Impurities	≤0.50%	Conforms
NMR Spectrum 1H	Conforms to structure	Conforms
Test Standard	The product has been tested and complies with the given specifications
Usage	Pharmaceutical Intermediate; Dasatinib / Moxonidine Intermediate

1780-26-3 - Synthetic Route:

4,6-Dichloro-2-Methylpyrimidine (CAS: 1780-26-3) Synthetic Route

Solvents used in the production process Petroleum Ether

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

1780-26-3 - Risk and Safety:

Risk Codes
R34 - Causes burns
R51/53 - Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.
R43 - May cause sensitization by skin contact
R22 - Harmful if swallowed
Safety Description
S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection.
S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
S61 - Avoid release to the environment. Refer to special instructions / safety data sheets.
S36/37 - Wear suitable protective clothing and gloves.
UN IDs UN 3261 8/PG 2
WGK Germany 3
HS Code 2933599099
Hazard Class 8
Packing Group III

1780-26-3 - Application:

4,6-Dichloro-2-Methylpyrimidine (CAS: 1780-26-3) is used in the synthesis of pharmaceutical intermediates and APIs. Preparation Products: Moxonidine (CAS: 75438-57-2); Dasatinib (CAS: 302962-49-8); Dasatinib Monohydrate (CAS: 863127-77-9); 4-Chloro-2,6-Dimethylpyrimidine (CAS: 4472-45-1); 4-Amino-6-Chloro-2-Methylpyrimidine (CAS: 1749-68-4). Moxonidine is a new type of antihypertensive drug, commonly used in the treatment of essential hypertension. Compared to the older central-acting antihypertensives, Moxonidine binds with much greater affinity to the imidazoline I1-receptor than to the α2-receptor. Dasatinib is an oral potent oncogenic kinase inhibitor, which can block signal of cancer cell replication acceleration , in May 2009, the US Food and Drug Administration (FDA) formally approved the sale of dasatinib , It has been clinically used for the treatment of various chronic myeloid leukemia (CML), including treatment of chronic myeloid leukemia which is resistant or intolerant to the treating programs including imatinib mesylate., Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) and the treatment of patients with solid tumors.